Skip to content
Clinical Trials – home
Not yet recruiting

Reduced‑Dose Enoxaparin Sodium Compared with Full Dose for Treating Deep Vein Thrombosis in Pregnant Women

Verified siteFast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Deep vein thrombosis is a condition where a blood clot forms in a deep vein, most often in the leg, and it can be more common during pregnancy. The study uses enoxaparin sodium, a medication that belongs to the class of low molecular weight heparin and is given as a small injection under the skin to prevent the clot from growing and to reduce the chance of new clots forming.

The purpose of the study is to find out whether a slightly lower dose of the medication works as well as the full dose in stopping another clot, including a clot that could travel to the lung called pulmonary embolism, after an initial six‑week period of full‑dose treatment. Participants will first receive the standard dose for six weeks, then they will be randomly assigned to continue either the standard dose or a reduced dose until after delivery, and they will be followed until about 12 weeks after the baby is born (postpartum) to see if any new clot occurs. The study also watches for serious side effects such as major bleeding, noticeable but less serious bleeding known as clinically relevant non-major bleeding, and heavy bleeding after birth referred to as postpartum haemorrhage. Simple explanations are provided during the study to help participants understand these terms.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Start Therapeutic Enoxaparin Treatment

    After joining the study, you will receive an injection of enoxaparin sodium under the skin.

    The initial dose is 8000 international units (IU) given twice a day, for a total of 16000 IU each day.

    This treatment is intended to treat your deep vein thrombosis.

  2. Step 2

    Initial Six‑Week Therapeutic Phase

    You will continue the twice‑daily injections for six weeks.

    During this period, you will attend scheduled visits where the medical team will check your symptoms and may perform ultrasound examinations to monitor the clot.

  3. Step 3

    Randomization to Dose Group

    At the end of the six‑week period, you will be randomly assigned to either the reduced‑dose group or the full‑therapeutic‑dose group.

    The assignment is done by the study system and you will not know which group you are in.

  4. Step 4

    Continuation of Assigned Dose Until 12 Weeks Postpartum

    If you are placed in the reduced‑dose group, you will receive 4000 IU of enoxaparin twice a day (total 8000 IU per day).

    If you remain in the full‑therapeutic‑dose group, you will continue the same 8000 IU twice daily (total 16000 IU per day).

    You will keep injecting the medication until 12 weeks after you give birth.

  5. Step 5

    Ongoing Monitoring During Pregnancy and Postpartum

    Regular visits will be scheduled to assess for new clot events, such as recurrent deep vein thrombosis or pulmonary embolism (PE).

    The team will also evaluate for major bleeding, clinically relevant non‑major bleeding, and postpartum hemorrhage according to standard definitions.

  6. Step 6

    Final Study Assessment

    At 12 weeks after delivery, a final evaluation will be performed to determine whether any symptomatic recurrent venous thromboembolism (VTE) occurred.

    The study will also record any bleeding complications that happened during the follow‑up period.

Who can join the trial?

5 criteria

  • You had your first clot in a large vein of the leg, called a proximal deep vein thrombosis, while you were pregnant between the 5th and 30th gestational weeks (the weeks counted from the start of your pregnancy).
  • You are currently pregnant.
  • You are 18 years old or older.
  • You can be of any ethnic background.
  • You agree to sign the informed consent form, which shows you understand the study and agree to take part.

Who cannot join the trial?

15 criteria

  • Unable or unwilling to sign a written informed consent form (the document that shows you agree to join the study).
  • Already taking part in another interventional clinical trial (being in a different research study at the same time).
  • Having active bleeding that could be dangerous (currently bleeding in a way that could cause problems).
  • Having a very low platelet count, called severe thrombocytopenia (fewer than 50 × 10⁹ platelets per liter), which makes it hard for your blood to clot.
  • Having a past or suspected reaction called heparin‑induced thrombocytopenia (HIT), where a blood thinner (heparin) caused a drop in platelets.
  • Having an absolute contraindication to blood thinners (anticoagulation) or low‑molecular‑weight heparin (LMWH), including a known allergy to these medicines.
  • Having severe kidney problems, measured as an eGFR below 30 mL/min/1.73 m², which means the kidneys cannot clear the medication properly.
  • Having active cancer (malignancy) or cancer that needs chemotherapy or radiation therapy.
  • Having a medical condition that is immediately life‑threatening (a serious illness that could cause death right away).
  • Having a blood clot in the lungs at the start of the study, known as a pulmonary embolism.
  • Having severe thrombophilia, a strong tendency to form blood clots, as defined by the study protocol.
  • Having an acute or ongoing chronic disease that could interfere with the study results.
  • Having an inferior vena cava filter, a small device placed in a large vein to catch clots.
  • Needing long‑term blood‑thinning medication for reasons other than the current clot (deep vein thrombosis).
  • Having serious heart or lung problems, classified as NYHA class III–IV (advanced heart failure or severe breathing difficulty).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Enoxaparin is a low‑molecular‑weight heparin that is given as an injection under the skin. It works by thinning the blood so that clots do not get larger and new clots are less likely to form. In this study, pregnant women who have already had a deep vein clot receive enoxaparin after an initial six‑week period of full‑dose treatment, and the researchers are testing whether a reduced dose can keep them safe from another clot.

What is already known about the treatment

Enoxaparin sodium - Enoxaparin sodium is given as a subcutaneous injection, usually in a pre‑filled syringe containing a liquid solution. It is a low‑molecular‑weight heparin that is widely used and well documented for preventing and treating blood clots, especially deep vein thrombosis, and is approved in many countries. It works by binding to antithrombin and enhancing its ability to block clot‑forming enzymes, mainly factor Xa, which slows down clot formation. It is classified as an anticoagulant, specifically a low‑molecular‑weight heparin.

Investigated diseases

Deep vein thrombosis - Deep vein thrombosis is a condition where blood clots develop in the deep veins, most often in the legs. It can cause swelling, pain, and a feeling of warmth in the affected limb. As the clot enlarges, it may extend along the vein or break free and travel to the lungs, leading to a pulmonary embolism. The condition frequently starts after periods of reduced movement, injury to the vein, or other factors that slow blood flow. Over weeks to months, the clot may shrink and be replaced by scar tissue, which can alter normal blood flow.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2025-521566-10-00Protocol codeAPRICOTEstimated enrolment120 patientsSponsorCasa Sollievo Della Sofferenza

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.